Controlled, double-blind, randomized, dose-rangig study of once-daily regimen of BAY 59-7939 in the prevention of VTE in patients undergoing elective total hip replacement - ODIXaHIP-OD study

• Conditions: Prevention of VTE in patients undergoing elective total hip replacement; MedDRA version: 9.1Level: HLGTClassification code 10014523Term: Embolism and thrombosis

• Registration Number: EUCTR2004-001341-14-IT
• Lead Sponsor: BAYER

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-12-16
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 670

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Valutare lefficacia e la tollerabilita' di quattro dosaggi di BAY 59-7939 verso enoxaparina nella prevenzione della trombosi venosa profonda in pazienti sottoposti a chirurgia ortopedica maggiore per protesi dellanca. <br><br>;Secondary Objective: ;Primary end point(s): DVT, embolia polmonare e morte